Considering the promising therapeutic effects of DKK1 neutralization in patients with gastric and endometrial cancer (NCT04363801, NCT03395080), DKK1 targeting should be investigated as a therapeutic option for patients with breast cancer. The gene discussed is DKK1; the disease is breast cancer.